* Yield10 Bioscience Inc YTEN.OQ YTEN.O is expected
to show a
fall in quarterly revenue when it reports results on August
14.
* The Woburn Massachusetts-based company is expected to
report a
67.6% decrease in revenue to $33.33 thousand from $103 thousand
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Yield10 Bioscience
Inc is
for a loss of 54 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Yield10
Bioscience Inc is $12, above its last closing price of $0.45.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.63 -0.63 -0.76 Missed -20
Dec. 31 2023 -0.69 -0.60 -0.67 Missed -10.7
Sep. 30 2022 -0.65 -0.65 -0.71 Missed -9.2
Jun. 30 2022 -0.69 -0.69 -0.70 Missed -1.4
Mar. -0.65 -0.65 -0.68 Missed -4.2
31 2022
Dec. 31 2021 -0.64 -0.63 -0.61 Beat 3.9
Sep. 30 2021 -0.65 -0.65 -0.49 Beat 24.6
Jun. 30 2021 -0.54 -0.54 -0.64 Missed -18.5
This summary was machine generated August 12 at 02:06 GMT. All
figures in US dollars unless otherwise stated